Salix Coronary Plaque vs PMcardio
AI Verdict
Choose Salix Coronary Plaque if…
Choose Artrya Salix Coronary Plaque if your institution performs CCTA scans and requires rapid, AI-driven analysis of coronary artery plaque and stenosis at the point of care. This tool is ideal for quickly identifying and quantifying high-risk plaque features, aiding in the diagnosis and management of coronary artery disease, and streamlining workflow with automated report generation.
View Salix Coronary Plaque →Choose PMcardio if…
Choose PMcardio if your clinical setting requires immediate, AI-powered interpretation of ECGs for a wide range of cardiac conditions, especially in emergency or primary care environments where rapid decision-making is crucial. It is well-suited for healthcare professionals who need an 'expertise extender' to confidently and quickly diagnose over 50 cardiac conditions, including subtle STEMI and reduced LVEF, and to guide patient management recommendations.
View PMcardio →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Salix Coronary Plaque | PMcardio |
|---|---|---|
| Pricing | Contact for pricing | Freemium |
| Deployment | Cloud | Mobile app (iOS and Android), Web platform, Enterprise integrations with EHR/CVIS and EMS systems |
| FDA Status | Yes AI-estimated | Pending AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
PMcardioPMcardio offers a mobile app (iOS and Android) and a web platform, allowing for flexible access and ease of use at the point of care, even supporting ECG digitization via smartphone camera. Artrya Salix Coronary Plaque is a web-based software, which is also accessible, but PMcardio's mobile-first approach and ability to digitize ECGs from photos provides broader immediate usability for clinicians in various settings.
Clinical Value
PMcardioPMcardio is clinically validated in over 25 studies and detects over 50 cardiac conditions from ECGs, including STEMI/OMI with high sensitivity and reduced false alarms. Artrya Salix Coronary Plaque provides near real-time assessment of coronary artery plaque and stenosis from CCTA scans, identifying high-risk plaque features, and is FDA-cleared. While both offer significant clinical value, PMcardio's broader range of detectable conditions and extensive clinical validation, including RCTs, gives it an edge.
Pricing & Value
PMcardioPMcardio offers a freemium model with a free plan for 5 ECG analyses per month, making it accessible for individual clinicians to try and use. Artrya Salix Coronary Plaque requires contacting for pricing, with a per-scan assessment model that has a US CPT reimbursement rate of US$950, indicating a higher cost barrier for initial access.
Enterprise Readiness
PMcardioPMcardio offers an 'Organizations' plan with enterprise-ready deployment, including integration with existing ECG systems, EHR/CVIS, EMS systems, role-based access control, SSO, and full audit trails. Artrya Salix Coronary Plaque is a cloud-based solution that integrates with existing imaging systems and has strategic partnerships with hospital systems, but PMcardio's explicit mention of comprehensive integration features and security compliance (SOC 2 Type II, ISO 27001, GDPR, HIPAA) demonstrates a more robust enterprise readiness.
Innovation
PMcardioPMcardio features AI explainability with heatmaps (ECGxplainu2122) to show how the AI reached its diagnosis, and its 'Queen of Hearts' AI model has received FDA Breakthrough Device Designation for STEMI detection. Artrya Salix Coronary Plaque offers AI-enabled CCTA analysis for plaque and stenosis, including high-risk plaque features, and aims to be the only company offering point-of-care for both plaque and blood flow. PMcardio's explainable AI and Breakthrough Device Designation highlight a strong innovative edge in its specific domain.
Support & Docs
PMcardioPMcardio provides a comprehensive Help Center, FAQ, and regulatory/security documentation readily available on its website. While Artrya mentions automated report generation and integrated workflow management, specific details about user support and documentation are not as explicitly detailed in the provided information.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Salix Coronary Plaque | PMcardio |
|---|---|---|
| Tool Name | Salix Coronary Plaque | PMcardio |
| Company | Artrya Limited | Powerful Medical |
| Description | FDA-cleared, AI-driven, web-based software that provides near real-time, point-of-care assessment of coronary artery plaque and stenosis from CCTA scans, aiding in the rapid and accurate diagnosis of coronary artery disease. | CE-certified AI platform that interprets ECGs to assess over 50 cardiac conditions rapidly and accurately. Clinically validated in more than 25 studies and trusted by over 100,000 clinicians, it delivers rapid, expert-level interpretations, empowering various healthcare professionals to act with confidence at the point of care. |
| Primary Function | AI-enabled CCTA analysis for coronary artery plaque and stenosis assessment | AI-powered ECG interpretations for over 50 cardiac conditions |
| Regulatory Clearance | FDA-cleared | CE-certified |
| Key Features (Examples) | Near real-time, point-of-care assessment; Detection and quantification of coronary plaque; Identification of high-risk plaque features; Stenosis assessment; Quantification of calcifications (calcium scoring); Automated report generation. | Instant AI-powered ECG interpretations; Detection of 50+ ECG findings (including STEMI/OMI, rhythms, reduced LVEF, conduction disorders); Visual AI Explainability with heatmaps; Automatic analysis of heart rate, axis, P wave, PR, QRS, and QT/QTc intervals; Culprit Artery AI confidence scores with 3D heart visualization. |
Videos
Demos, reviews, and walkthroughs featuring Salix Coronary Plaque and PMcardio.